About
Qureight is an AI-powered imaging CRO built to accelerate the development of life-saving therapies in lung and heart disease. Its enterprise-grade platform combines automated image management, deep-learning biomarker analysis, and real-world data science into a single end-to-end solution for clinical trials. The platform's three core product lines address the full lifecycle of clinical imaging research. Global Imaging CRO Services provides a high-performance infrastructure for onboarding global trial sites and evaluating participants in days rather than weeks. AI-Powered Endpoints & Analytics delivers proprietary lung image biomarkers—Lung8™, Air8™, Fibr8™, Glass8™, and Vascul8™—purpose-built for tracking treatment response, predicting disease progression, and reporting baseline disease severity. Data Science Products leverages some of the largest real-world datasets in IPF, PPF, PH, and Bronchiectasis to create synthetic control arms, enabling robust efficacy assessment where placebo arms are impractical or unethical. Qureight's therapeutic focus spans Interstitial Lung Diseases (including IPF and CTD-ILD), Pulmonary Hypertension, and Bronchiectasis. Its tools are designed for biopharma and biotech enterprises that need reliable imaging biomarkers, data quality control, KOL advisory support, central reads, and endpoint discovery—all within a single, scalable platform built for regulatory-grade clinical trial contexts.
Key Features
- AI-Powered Lung Biomarkers: Proprietary deep-learning biomarkers (Lung8™, Air8™, Fibr8™, Glass8™, Vascul8™) quantify disease severity, track treatment response, and predict long-term clinical outcomes in lung disease trials.
- Global Imaging CRO Services: A scalable, high-performance imaging platform with workflow tools that rapidly onboard global trial sites and accelerate participant evaluation from weeks to days.
- Synthetic Control Arms: Leverages access to some of the largest real-world datasets in IPF, PPF, PH, and Bronchiectasis to build synthetic control arms for trials where placebo groups are impractical or unethical.
- End-to-End Data Curation: Automated image ingestion, data quality control, and curation pipeline ensuring regulatory-grade data integrity across radiology and clinical biomarker workflows.
- Endpoint Discovery & Analytics: Supports biopharma in identifying novel imaging endpoints, designing early-phase drug trials, and conducting toxicity analysis using real-world clinical imaging data.
Use Cases
- Biopharma companies running Phase II/III clinical trials in IPF or PPF needing AI-powered imaging endpoints and automated central read workflows.
- Clinical trial sponsors seeking synthetic control arms derived from real-world patient data to reduce placebo group requirements in rare lung disease studies.
- Biotech startups in early-stage drug development using Qureight's data science products for trial design, toxicity analysis, and endpoint discovery.
- Global multi-site clinical trials requiring rapid site onboarding and standardized imaging data quality control across radiology centers.
- Pulmonary Hypertension researchers needing quantitative imaging biomarkers to monitor disease progression and treatment response in longitudinal studies.
Pros
- Specialized Clinical Focus: Purpose-built for lung and heart disease clinical trials, offering deep domain expertise and validated AI biomarkers in highly specialized therapeutic areas like IPF and Pulmonary Hypertension.
- End-to-End Platform: Covers the full trial imaging workflow—from site onboarding and image management to AI analysis, central reads, and data science products—reducing the need for multiple vendors.
- Real-World Data Access: Commercial access to large real-world datasets enables synthetic control arms and robust trial design insights that are difficult to replicate with traditional CRO approaches.
- Speed to Enrollment: Proprietary infrastructure accelerates participant inclusion and site onboarding, compressing timelines from weeks to days in global multi-site trials.
Cons
- Narrow Therapeutic Scope: Qureight is specialized in lung and heart diseases only; biopharma companies working in other therapeutic areas cannot leverage the platform's full capabilities.
- Enterprise-Only Pricing: As an enterprise CRO service with no self-serve or freemium tier, smaller biotech startups or academic researchers may find access and costs prohibitive.
- Limited Public Documentation: Technical specifications, integration details, and pricing are not publicly available, requiring direct engagement with the Qureight sales team before evaluation.
Frequently Asked Questions
What therapeutic areas does Qureight support?
Qureight currently focuses on Interstitial Lung Diseases (including Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis), Pulmonary Hypertension, and Bronchiectasis.
What are Qureight's proprietary AI biomarkers?
Qureight offers five deep-learning lung image biomarkers: Lung8™, Air8™, Fibr8™, Glass8™, and Vascul8™. These are purpose-built for interventional clinical trials to track treatment response, predict disease progression, and assess baseline disease severity.
What is a synthetic control arm and how does Qureight use it?
A synthetic control arm uses real-world patient data to simulate a placebo or comparator group in a clinical trial, making it viable when traditional placebo arms are impractical, unethical, or inefficient. Qureight builds these using its access to large real-world datasets in IPF, PPF, PH, and Bronchiectasis.
How quickly can Qureight onboard clinical trial sites?
Qureight's proprietary infrastructure is designed to rapidly onboard global trial sites and evaluate participants in days rather than the weeks typically required by traditional CRO imaging workflows.
Who is Qureight designed for?
Qureight is designed for biopharma and biotech companies conducting interventional clinical trials in lung and heart disease, as well as organizations seeking imaging CRO services, AI-powered endpoint analysis, or real-world data science support for drug development.
